title: The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.
abstract: Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than 65 years and have no significant comorbidities. In this article, we review the role of FCR in the current treatment paradigm for CLL.
authors.affiliation: Division of Lymphoma, John Theurer Cancer Center, Blood and Marrow Transplantation Program, John Theurer Cancer Center at Hackensack University Medical Center, 92 Second Street, Hackensack, NJ 07624, USA.
authors.forename: Alan P
authors.initials: AP
authors.lastname: Skarbnik
authors.affiliation: Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
authors.forename: Stefan
authors.initials: S
authors.lastname: Faderl
keywords: CLL; FCR; chemoimmunotherapy; fludarabine; rituximab